NYTIMES (Gina Kolata and Rebecca Robbins) - F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
NEWSNATIONNOW (Zach Kaplan) - Thyroid tablets recalled nationwide over potential 'superpotency': FDA
Patients taking the affected lot are advised not to discontinue use without first consulting their health care provider.
YOUTUBE (Fox Business) - VACCINE BREAKTHROUGH: Personalized cancer treatment takes major leap
Moderna CEO Stéphane Bancel joins ‘Mornings with Maria’ to discuss the company's landmark cancer vaccine partnership with Merck. Bancel details the promising Phase 3 melanoma trial results and outlines Moderna's latest financial growth outlook. #foxbusiness #morningswithmaria 0:03 – Moderna and Merck’s Personalized Cancer Vaccine Breakthrough 1:18 – Moderna Targets FDA Approval for Next Year 2:20 – Expanding mRNA Cancer Treatment Beyond Melanoma 5:21 – Moderna’s mRNA Push: Rare Diseases and a New Flu Vaccine 7:27 – Personalized Vaccine Costs, Manufacturing and Moderna’s Growth Outlook
HUFFPOST - New Melanoma Vaccine Shows Promise In Fighting Cancer, Preventing Recurrence
“It’s very exciting,” a melanoma expert said of the experimental cancer vaccine announced by pharmaceutical companies Moderna and Merck.
“It’s very exciting,” a melanoma expert said of the experimental cancer vaccine announced by pharmaceutical companies Moderna and Merck.Open
NYTIMES (Rebecca Robbins) - Moderna’s Shift to Cancer Company Lifts Stock Up 177%
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
YOUTUBE (LiveNOW from FOX) - Moderna, Merck shares soar on success of mRNA cancer vaccine
Moderna and Merck’s mRNA cancer vaccine showed positive results in a late-stage melanoma trial. The vaccine could be available as soon as next year if regulators approve it. Moderna shares surged as much as 160% following the results. Moderna developed the vaccine with Merck and tested it together with Keytruda, a common immunotherapy treatment for melanoma. This is the first successful late-stage trial for an mRNA cancer vaccine. The vaccine works by training a patient’s immune system to recognize and attack specific mutations in cancer cells. It is also the first study to show that adding another treatment to Keytruda worked better than Keytruda alone. Similar vaccines are being studied for lung, breast and pancreatic cancers.…
DAILYCALLER (Jack McGeever) - Moderna Stock Skyrockets Over 100%
Shares of Moderna more than doubled Wednesday
AXIOS (Adriel Bettelheim) - AI brings savings to clinical trials: study
Artificial intelligence isn't just speeding up early-stage drug development, it's starting to unlock millions of dollars' worth of new efficiencies in clinical trials on cancer treatments, research shared first with Axios shows. Why it matters: AI-powered tools could shave months off time-consuming processes like recruiting and enrolling patients, monitoring results and interpreting data. - That could free up resources for more clinical studies and possibly lower the high failure rate for new drugs. What they found: A new Tufts Center for the Study of Drug Development analysis found AI agents can accelerate clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in…
Artificial intelligence isn't just speeding up early-stage drug development, it's starting to unlock millions of dollars' worth of new efficiencies in clinical trials on cancer treatments, research shared first with Axios shows. Why it matters: AI-powered tools could shave months off time-consuming processes like recruiting and enrolling patients, monitoring results and interpreting data. - That could free up resources for more clinical studies and possibly lower the high failure rate for new drugs. What they found: A new Tufts Center for the Study of Drug Development analysis found AI agents can accelerate clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in…Open
JUSTTHENEWS (Greg Piper) - Return of the rubber stamp? First mRNA flu vaccine has far higher injury rate than standard jabs
Moderna's own research shows 5,000 novel jabs required to prevent one hospitalization over standard vaccine. "Pharma finished recapturing" FDA after exit of officials with higher standards, drug industry journalist says.
NEWSNATIONNOW (Nathaniel Weixel and The Hill) - FDA approves first mRNA flu vaccine
The agency approved the shot for two separate age groups: People age 50 to 64, and for 65 years and older.